Access to Medicine

KEI submissions to the UN Secretary General’s High Level Panel on Access to Medicine

Posted on by James Love

Attached below are the four submissions for which KEI was the lead author to the UN Secretary General’s High Level Panel (HLP) on Access to Medicine.

  1. “The Need for Global Negotiations on Agreements to Fund R&D within the Context of a Progressive De-linking of R&D Costs from Product Prices”. Supported by 12 organizations; 1 individual; 3 Members of European Parliament.
  2. “Increasing the Transparency of Markets for Drugs, Vaccines, Diagnostics and other Medical Technologies”. Supported by 17 organizations; 2 individuals; 3 Members of European Parliament.

    3. Continue Reading →

Xtandi 2016 March-In Request

Posted on by James Love

Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise either their royalty-free, non-exclusive license or federal “march-in” rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.

Xtandi was invented at UCLA on federal grants from the NIH and DoD.

Continue Reading →

What’s wrong with current system of funding R&D, and what are ideas for reforms?

Posted on by James Love

I was recently asked by OSF to write a two page document that described “what was wrong with the current system of funding R&D?” and to offer some “important ideas for change.” This was my two page submission.

What is wrong with the current system for funding R&D? What are the most important ideas for change?
(In two pages, for OSF meeting on drug development)

James Love
October 20, 2015

1. What is wrong with the current system for funding R&D?

Continue Reading →

US, AU and CA try to block WTO LDC drug patent waiver because PhRMA’s not happy enough with the TPP

Posted on by Thiru

Members of the World Trade Organization (WTO) meet this week in Geneva (15 October 2015 – 16 October 2015) to decide if the poorest countries on earth are exempt from WTO rules for pharmaceutical patents. The WTO’s TRIPS Council is expected to make a decision in respect of the request of the LDC Group’s request for indefinite exemption from TRIPS obligations on pharmaceutical patents. Continue Reading →

Press Release: Coalition for Affordable T-DM1 Asks UK Government to grant compulsory licenses on Roche breast cancer drug

Posted on by James Love

Press Release: Coalition for Affordable T-DM1 Asks the UK Government to Employ Crown Use Authority to Lower Price of Expensive Cancer Drug sold by Roche

CONTACT:

Diarmaid McDonald
email: accessdiarmaid@gmail.com
+44.7894.4557.81

Susannah Markandya
email: s.markandya@gmail.com
+44.7811.9573.12

Zack Struver
email: zack.struver@keionline.org
Cell: +1.914.582.1428
Office: +1.202.332.2670 (between 2:00 PM and 10:00 PM BST)

Continue Reading →

Senator Bernie Sanders proposal to expand Veterans access to patented medical inventions

Posted on by KEI Staff

This is a video by Zack Struver about Senator Bernie Sander’s proposal to expand Veterans access to patented medical inventions. The video discusses both the proposal by Senator Sanders to give the U.S. Department of Veterans Affairs the authority to use compulsory licenses on patents on medical inventions, including drugs, and the history of “government use” provisions in current U.S. statutes, including 28 U.S.C. 1498, which Sanders proposes modifying.

Continue Reading →